Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Management of patients with protein s deficiency : focus on clinical course and direct oral anticoagulant
Authors:ID Altamura, Nicola (Author)
ID Di Girolamo, Filippo Giorgio (Author)
ID Pradella, Paola (Author)
ID Cavalet, Martina (Author)
ID Pellicori, Federica (Author)
ID Vinci, Pierandrea (Author)
ID Panizon, Emiliano (Author)
ID Cominotto, Giovanni (Author)
ID Teraž, Kaja (Author)
ID Biolo, Gianni (Author)
Files:URL URL - Source URL, visit https://link.springer.com/article/10.1186/s12959-026-00861-w
 
.pdf PDF - Presentation file, download (1,14 MB)
MD5: 467D07E7957F5645EAA3D96D2C14CAF1
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo ZRS Koper - Science and Research Centre Koper
Abstract:Background Protein S (PS) is a cofactor of protein C (PC) which, when activated to activated PC (APC), mainly acts to degrade coagulation factor Va and VIIIa, and its deficiency may trigger an array of venous thromboembolic events (VTE); when unprovoked and life-threatening, these need indefinite anticoagulation. Direct oral anti coagulants (doac) are efficient drugs in therapy and prevention of VTE, although the optimal prophylactic doses in different conditions are not identified. Methods General characteristics and clinical events of 33 PS deficient patients (7 uneventful, 10 carrying also other thrombophilic conditions) were recorded from their medical records. Patients suffering from VTE underwent LMWH/Fondaparinux therapy followed by a full dose of doac (apixaban or rivaroxaban) and then a reduced dose doac (apixaban and rivaroxaban). Results Average, lowest and highest PS levels measured during follow-up were higher in male patients (p = 0.001). The cumulative prevalence of patients taking drugs acting on central nervous system (opioids, antidepressants, antiepileptic, antimigraine, antipsychotic) was 33%. Three minor hemorrhages were observed during the full-dose and one during the reduced doac therapy, while 3 VTE (1 pulmonary embolism and 2 deep venous thrombosis) occurred exclusively during the reduced-dose doac therapy (p = 0.033 Vs Full dose, 8.1 100patient/yr 95% CI 4–15). Compliance during the reduced-dose therapy was good according to the circulating levels of doac. In survival analysis, the only variable associated with VTE recurrence was PS deficiency combined with thrombophilic defects (p = 0.049). Conclusions Free PS deficiency affects the quality of life in many ways and a low dose doac in PS deficient patients is only partially effective in secondary prevention of VTE.
Keywords:thrombophilia, reduced-dose DOAC, bleeding, thromboembolic events
Publication status:Published
Publication version:Version of Record
Article acceptance date:24.03.2026
Publication date:14.04.2026
Year of publishing:2026
Number of pages:10 str.
Numbering:Vol. 24, [no.] 39
PID:20.500.12556/DiRROS-29003 New window
UDC:577.2:612
ISSN on article:1477-9560
DOI:10.1186/s12959-026-00861-w New window
COBISS.SI-ID:275432195 New window
Copyright:© The Author(s) 2026.
Note:Nasl. z nasl. zaslona; Soavtorji: Di Girolamo Filippo Giorgio, Pradella Paola, Cavalet Martina, Pellicori Federica, Vinci Pierandrea, Panizon Emiliano, Cominotto Giovanni, Zaccari Michele, Galasso Irma, La Rocca Paola, Teraž Kaja, La Raja Massimo, Fiotti Nicola & Biolo Gianni; Opis vira z dne 16. 4. 2026;
Publication date in DiRROS:16.04.2026
Views:35
Downloads:22
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Thrombosis journal
Shortened title:Thromb J
Publisher:BioMed Central
ISSN:1477-9560
COBISS.SI-ID:2611220 New window

Licences

License:CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.
Licensing start date:14.04.2026

Secondary language

Language:Slovenian
Keywords:protein S, trombofilija, krvavitve, tromboembolični dogodki


Back